Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
University of Chicago Medical Center · WinnMed · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,714
total citations
- FWCI
- 65.48
- Percentile
- 100%
- References
- 33
Citations per year
Authors
9Topics & keywords
Topics
Keywords
- Adalimumab
- Monoclonal antibody
- Medicine
- Crohn's disease
- Tumor necrosis factor alpha
- Monoclonal
- Necrosis
- Disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.